Get the Stockscreener App
15.60
0.52%
0.08
Carlsmed Inc stock is traded at $15.60, with a volume of 46,726.
It is up +0.52% in the last 24 hours and up +16.16% over the past month.
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
See More
Previous Close:
$15.52
Open:
$15.38
24h Volume:
46,726
Relative Volume:
0.28
Market Cap:
$425.92M
Revenue:
$56.44M
Net Income/Loss:
$-32.60M
P/E Ratio:
-12.66
EPS:
-1.2318
Net Cash Flow:
$-35.15M
1W Performance:
-7.58%
1M Performance:
+16.16%
6M Performance:
+20.09%
1Y Performance:
+20.84%
1-Day Range:
$15.38
$15.88
1-Week Range:
$15.38
$17.20
52-Week Range:
$8.50
$17.23
Carlsmed Inc Stock (CARL) Company Profile
Name
Carlsmed Inc
Sector
Industry
Phone
858-295-9290
Address
1800 ASTON AVENUE, CARLSBAD
Compare CARL vs VEEV, BTSG, TEM, TXG, HQY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
15.60 | 450.50M | 56.44M | -32.60M | -35.15M | -1.2318 |
VEEV
Veeva Systems Inc
|
275.09 | 40.70B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
60.73 | 11.78B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
64.62 | 12.03B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
62.65 | 8.32B | 638.78M | -22.66M | 122.18M | -0.1744 |
HQY
Healthequity Inc
|
96.07 | 8.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Initiated | BTIG Research | Buy |
| Aug-18-25 | Initiated | BofA Securities | Buy |
| Aug-18-25 | Initiated | Goldman | Buy |
| Aug-18-25 | Initiated | Piper Sandler | Overweight |
| Aug-18-25 | Initiated | Truist | Buy |
Carlsmed Inc Stock (CARL) Latest News
Carlsmed, Inc. (NASDAQ:CARL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wall Street Zen Upgrades Carlsmed (NASDAQ:CARL) to "Hold" - MarketBeat
Carlsmed (CARL) plans up to $250M in stock, debt and warrant sales - Stock Titan
Carlsmed (CARL) Holds Steady Near $13.72 as Tight Range Signals Potential MoveDefined Outcome ETF - vinanet.vn
Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform - TradingView
Transcript : Carlsmed, Inc. Presents at Bank of America SMID Cap Virtual Conference, Aug-12-2026 11 - marketscreener.com
CARL: Personalized AI spine surgery platform accelerates growth with new reimbursement and strong clinical data - TradingView
Carlsmed, Inc. Common Stock (NASDAQ: CARL) Share Price, CARL Stock News, CARL Share Price & Updates - Kalkine
Truist raises Carlsmed stock price target on strong growth outlook By Investing.com - Investing.com South Africa
Carlsmed Buy Rating Reaffirmed as 2026 Outlook Raised and Adoption Grows; $17 Price Target Maintained - TipRanks
Carlsmed (CARL) Stock Revenue Surge Meets A Wider Loss Per Share - Sahm
Carlsmed Q2 2026 revenue up 57% to USD 18.9M - Medical Buyer
Truist raises Carlsmed stock price target on strong growth outlook - Investing.com Nigeria
CARLSMED INC Q2 NET INCOME USD -10.5 MILLION - Moomoo
Truist Adjusts Price Target on Carlsmed to $20 From $18, Maintains Buy Rating - marketscreener.com
Carlsmed, Inc. Stock 12‑Month Price Target Raised to $19.2, Implies 42% Upside - TradingView
Carlsmed Inc. (CARL) Advances 4.79% to $14.21: Personalized Spine Tech Gains TractionSeasonality Effect - dars.gov.et
Carlsmed Inc (CARL) (Q2 2026) Earnings Call Highlights: Revenue Surges 57% to $18. ... - Yahoo Finance UK
Carlsmed Q2 Earnings Call Highlights - Yahoo Finance
Carlsmed, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
CARLSMED, INC. Q2 2026: Revenue $18.94M, EPS $(0.39) — 10-Q Summary - TradingView
Carlsmed reports Q2 2026 revenue $18.9M, raises full-year guidance to $74–$78M - TradingView
Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance - The Manila Times
Carlsmed, Inc. Raises Earnings Guidance for the Fiscal Year 2026 - marketscreener.com
Carlsmed, Inc. $CARL Stock Holdings Lifted by Janus Henderson Group PLC - MarketBeat
Carlsmed (CARL) Earnings Date and Reports 2026 $CARL - MarketBeat
Carlsmed (CARL) Gains Favorable CMS Reimbursement Policy Boostin - GuruFocus
Carlsmed, Inc. expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures - The Manila Times
Carlsmed Inc. (CARL) Holds Near $12.59 as Support and Resistance Levels TightenSmart Money Flow Stocks - dars.gov.et
Will Carlsmed, Inc. (CARL) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Carlsmed, Inc. To Participate in Upcoming Investor Conferences - The Manila Times
Carlsmed, Inc. (NASDAQ:CARL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
CARL|Carlsmed Ord Shs|Price:10.800|Chg%:-0.200 - TradingKey
Carlsmed Inc. (CARL) Declines Slightly as Stock Nears Key Support LevelBox Spread - dars.gov.et
Carlsmed Ord Shs (CARL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Carlsmed Inc. (CARL) Q1 2026 Earnings: EPS Beat Provides Cautious Optimism Amid Ongoing Market VolatilityRevenue Per Share - dars.gov.et
KCM Capital Inc Invests $1.81 Million in Carlsmed, Inc. $CARL - MarketBeat
Carlsmed Inc. (CARL) Slips 1.72% as Stock Tests Support LevelsContinuation Pattern Picks - dars.gov.et
Carlsmed to report Q2FY26 results on August 5, 2026 - scanx.trade
Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026 - marketscreener.com
Carlsmed Inc. (CARL) Slips Over 2.8% as Resistance Holds Near $11.90Short Setup Alerts - dars.gov.et
Carlsmed Inc. Q1 2026 Earnings: Narrower-than-Expected Loss as Pre-Revenue Medtech Advances Personalized Spine PlatformSurprise Factor Analysis - dars.gov.et
Wall Street analysts think Carlsmed, Inc. (CARL) could surge 90.77%: Read this before placing a bet - MSN
Carlsmed Inc. (CARL) Q1 2026 Earnings: EPS Surpasses Estimates as Pre-Revenue Company Advances Development - dars.gov.et
Possible Turnaround For Carlsmed Insiders, Still Down US$1.7m - 富途牛牛
Gross profit of Carlsmed, Inc. – LS:A41CM7 - TradingView
Carlsmed Inc. (CARL) Slips 3.16% as Stock Trades Near Key Support LevelLiquidity Order Flow - po-news-eg.net
Carlsmed (CARL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CARL Initiates Coverage On Needham -- Rating Set to Buy - GuruFocus
Carlsmed Inc Stock (CARL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Carlsmed Inc Stock (CARL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cordonnier Michael | CEO, President |
Mar 02 '26 |
Option Exercise |
0.34 |
197,855 |
66,281 |
1,554,501 |
| Cordonnier Michael | CEO, President |
Mar 02 '26 |
Sale |
13.29 |
197,855 |
2,629,889 |
1,356,646 |
0.03%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):